Unlock stock picks and a broker-level newsfeed that powers Wall Street.
AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio
In This Article:
The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, potentially increasing access to treatment and reducing costs.
Terms and Privacy Policy